(Q36028318)

11 August 2017

1 reference

title

Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. (English)

1 reference

11 August 2017

liver transplantation

1 reference

1

Bruno Roche

1 reference

11 August 2017

2

Didier Samuel

1 reference

PubMed ID

15688164

11 August 2017

language of work or name

1 reference

2 February 2005

1 reference

11 August 2017

Transplant International

1 reference

11 August 2017

17

1 reference

11 August 2017

759-766

1 reference

11 August 2017

12

1 reference

The association between hepatitis C infection and survival after orthotopic liver transplantation

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

The course of hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

A longitudinal analysis of hepatitis C virus replication following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Impact of immunosuppressive therapy on recurrence of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Hepatitis C virus kinetics during and immediately after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Recurrence of hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Daily interferon therapy for hepatitis C virus infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Hepatitis C infection in patients undergoing liver retransplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Liver transplantation in patients with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Liver transplantation in adults coinfected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2004.TB00508.X

10.1111/J.1432-2277.2004.TB00508.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15688164